GSK banks on promis­ing da­ta from its PhI­II Gem­i­ni pro­gram to stare down Gilead on HIV — but there are plen­ty of skep­tics

Af­ter more than a decade’s worth of work, Glax­o­SmithK­line $GSK re­searchers to­day are un­veil­ing pooled da­ta from their two late-stage tri­als of a two-drug reg­i­men …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER